vTv Therapeutics starts phase 2 trial evaluating TTP273 to treat Type 2 diabetes
TTP273 is an oral, small molecule GLP-1R agonist with best-in-class potential. The previous Phase 1b trial of TTP273 demonstrated robust effects on postprandial and fasting glucose. All doses